Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

Journal of Clinical Oncology

Volumn 22, Issue 18, 2004, Pages 3694-3699

  Sverrisdottir A ^a   Fornander, T ^a   Jacobsson, H ^a   Von Schoultz, E ^a   Rutqvist, L E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; CANCER STAGING; DRUG POTENTIATION; MIDDLE AGED; OVARY; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OVARY; PREMENOPAUSE; TAMOXIFEN;

EID: 4644297698     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.148     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 348: 1189-1196, 1996
2. Rutqvist LE: The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years. Proc Am Soc Clin Oncol 18, 1999 (abstr 251)
3. The ZIPP International Collaborators' Group: Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the quot;zoladex"in premenopausal patients (ZIPP) trial. (in press)
4. Boccardo F, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
5. Jonat W: Role of LHRH agonists in pre-menopausal women with oestrogen receptor-positive breast cancer: The ZEBRA experience. Eur J Cancer 38:S39-S40, 2002 (suppl 6)
6. Jakesz R, Hausmaninger H, Samonigg H: Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. Eur J Cancer 38:327-332, 2002
7. Lindsay R, Hart DM, Aitken JM, et al: Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038-1041, 1976
8. Richelson LS, Wahner HW, Melton LJ III, et al: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273-1275, 1984
9. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001
10. Love RR, Mazess RB, Barden HS. et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
11. Bruning PF, Pit MJ, de Jong-Bakker M, et al: Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310, 1990
12. Headley JA, Theriault RL, LeBlanc AD, et al: Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6-11, 1998
13. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996
14. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351: 1451-1467, 1998
15. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984
16. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989
17. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990
18. Fornander T, Rutqvist LE, Wilking N: Effects of tamoxifen on the female genital tract. Ann N Y Acad Sci 622:469-476, 1991
19. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: The Scottish Breast Cancer Committee. BMJ 303:435-437, 1991
20. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
21. Fornander T, Rutqvist LE, Sjoberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019-1024, 1990
22. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
23. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
24. Lunar Corporation: Lunar DPX-L Operator's Manual. Madison, WI. Lunar Corporation.
25. Christiansen C, Riis BJ, Rodbro P: Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1108, 1987
26. Hansen MA, Overgaard K, Riis BJ, et al: Role of peak bone mass and bone loss in post-menopausal osteoporosis: 12 year study. BMJ 303:961-964, 1991
27. Riis BJ, Hansen MA, Jensen AM. et al: Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture - A 15-year follow-up study. Bone 19:9-12, 1996
28. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
29. LeBlanc AD, Schneider VS, Engelbretson DA, et al: Precision of regional bone mineral measurements obtained from total-body scans. J Nucl Med 31:43-45, 1990
30. Ambrahamsen B, Hansen TB, Jensen LB, et al: Site of osteodensitometry in perimenopausal women: Correlation and limits of agreement between anatomic regions. J Bone Miner Res 12:1471-1479, 1997
31. Ljunggren-Ribom E: Muscles, Estrogen and Bone (thesis). Uppsala, Sweden, Uppsala University, 2003
32. Nuti R, Martini G, Righi G, et al: Comparison of total-body measurements by dual-energy x-ray absorptiometry and dual-photon absorptiometry. J Bone Miner Res 6:681-687, 1991
33. Schott AM, Cormier C, Hans D, et al: How hip and whole-body bone mineral density predict hip fracture in elderly women: The EPIDOS prospective study. Osteoporos Int 8:247-254, 1998
34. Blake GM, Fogelman I: Bone densitometry and the diagnosis of osteoporosis. Semin Nucl Med 31:69-81, 2001
35. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936, 2002
36. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996
37. Klijn JG, Blarney RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
38. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997